Our strategic investments in several innovative ML/AI and data science companies will allow our development teams to identify unexpected synergistic drug combinations, repurpose existing drugs, discover novel drug targets, and accelerate opportunities into the clinic. We will use these capabilities to impact our own projects as well as new partnerships. This is one of our key competitive advantages as we reduce the cost and increase the speed with which new medicines get to patients.